PUBLIC CONTRACT · 2025
ADCM 5287/25 - Células CD3+aut.transd.anti-CD19 0.4-2x10e8 cél. Disp inj 68 ml (Brexucabtagene)
- Contract value
- €342,000.00
- Signed on
- 18 December 2025
- Procedure
- Direct award, general (Ajuste Direto Regime Geral)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 13604599PUBLISHED DESCRIPTION
ADCM 5287/25 - Células CD3+aut.transd.anti-CD19 0.4-2x10e8 cél. Disp inj 68 ml (Brexucabtagene) 1774625
Parties involved
- Place of performance
- Portugal, Porto, Porto
- NUTS region
- PT11A - Área Metropolitana do Porto
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- Gilead Sciences, Lda. · Tax ID 503604704
Values and timeline
- Contract price
- €342,000.00
- Procedure base price
- €342,000.00
- Total effective price
- Not reported on Portal BASE
- Publication date
- 24 February 2026
- Award date
- 18 December 2025
- Signing date
- 18 December 2025
- Performance period
- 20 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Direct award, general (Ajuste Direto Regime Geral)
- Award criterion
- Monofator
- CPV code
- 33000000-0 - Equipamento médico, medicamentos e produtos para cuidados pessoais
- Legal basis
- Artigo 24.º, n.º 1, alínea c) do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- Not stated
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 9648260
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.